Vertex Pharmaceuticals Incorporated (VRTX)
NASDAQ: VRTX · Real-Time Price · USD
447.50
-21.74 (-4.63%)
At close: Dec 18, 2024, 4:00 PM
394.95
-52.55 (-11.74%)
Pre-market: Dec 19, 2024, 7:59 AM EST
Vertex Pharmaceuticals Stock Forecast
Stock Price Forecast
The 25 analysts with 12-month price forecasts for VRTX stock have an average target of 519.88, with a low estimate of 408 and a high estimate of 600. The average target predicts an increase of 16.17% from the current stock price of 447.50.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for VRTX stock from 30 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 9 | 9 | 10 | 11 | 12 |
| Buy | 10 | 9 | 9 | 8 | 8 | 8 |
| Hold | 6 | 7 | 7 | 9 | 9 | 9 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 25 | 26 | 26 | 28 | 29 | 30 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Stifel | Stifel | Hold Maintains $490 → $494 | Hold | Maintains | $490 → $494 | +10.39% | Dec 16, 2024 |
| Jefferies | Jefferies | Hold → Strong Buy Upgrades $500 → $550 | Hold → Strong Buy | Upgrades | $500 → $550 | +22.91% | Dec 9, 2024 |
| Citigroup | Citigroup | Strong Buy Initiates $575 | Strong Buy | Initiates | $575 | +28.49% | Nov 14, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Sell Maintains $361 → $408 | Strong Sell | Maintains | $361 → $408 | -8.83% | Nov 6, 2024 |
| Scotiabank | Scotiabank | Hold Maintains $480 → $486 | Hold | Maintains | $480 → $486 | +8.60% | Nov 5, 2024 |
Financial Forecast
Revenue This Year
11.11B
from 9.87B
Increased by 12.54%
Revenue Next Year
12.05B
from 11.11B
Increased by 8.52%
EPS This Year
0.59
from 13.89
Decreased by -95.77%
EPS Next Year
19.14
from 0.59
Increased by 3,154.68%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 11.5B | 14.4B | 16.3B | |||
| Avg | 11.1B | 12.1B | 13.3B | |||
| Low | 10.6B | 11.0B | 11.6B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 16.8% | 29.8% | 35.2% | |||
| Avg | 12.5% | 8.5% | 10.1% | |||
| Low | 7.3% | -0.5% | -3.4% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 2.13 | 23.10 | 28.03 | |||
| Avg | 0.59 | 19.14 | 20.83 | |||
| Low | 0.05 | 15.95 | 16.73 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -84.7% | 3,828.9% | 46.5% | |||
| Avg | -95.8% | 3,154.7% | 8.8% | |||
| Low | -99.6% | 2,613.6% | -12.6% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.